Table 2.

Insulin and IGF measurements in BO cases and both control groups

	BO cases	GORD controls	Screening colonoscopy controls	Matched controls*	p Value†	p Value‡	p Value§
Insulin (μIU/ml)	10.2 (7.98)	9.1 (7.16)	7.4 (9.39)	7.9 (10.82)	0.33	0.001	0.082
HOMA-IR	2.78 (2.61)	2.23 (2.52)	1.86 (3.13)	1.84 (2.76)	0.13	<0.0006	0.013
IGF-1 (ng/ml)	173.4 (72.2)	194.1 (71.4)	116.5 (42.7)	119.3 (44.6)	0.03	<0.0001	<0.0001
IGFBP-1 (ng/ml)	14.7 (12.6)	14.5 (16.9)	30.1 (28.0)	29.7 (29.8)	0.88	<0.0001	<0.0001
IGFBP-3 (ng/ml)	3200 (945)	3721 (876)	3623 (833)	3475 (892)	<0.0001	<0.0001	0.16
Molar ratio of IGF-1:IGFBP-3	0.20 (0.07)	0.19 (0.06)	0.12 (0.03)	0.12 (0.04)	0.46	<0.0001	<0.0001

Values shown are mean (SD).

^*BO cases (N = 91) were selectively matched and compared with colonoscopy controls (N = 182) for age and waist-to-hip ratio.

^†p Value of difference between BO cases and GORD controls.

^‡p Value of difference between BO cases and colonoscopy controls.

^§p Value of difference between white male BO cases and matched colonoscopy controls.

BO, Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; HOMA-IR, homeostatic model for assessment of insulin resistance; IGF-1, insulin growth factor 1; IGFBP-1, IGFBP-3, IGF binding proteins 1 and 3.